Strategic partnerships drive early cancer detection in Singapore

These collaborations leverage technologies, such as next-generation sequencing.

New collaborations in Singapore have paved access to innovative methods for early-stage cancer detection.

According to GlobalData Medical Devices Analyst, Kanchan Chauhan, these partnerships with domestic and international organisations have helped leverage technologies, such as next-generation sequencing (NGS), to meet the urgent need for early detection methods.

“These partnerships enable the identification of cancer in its initial stages, facilitating timely interventions that greatly enhance prognosis and survival rates,” Chauhan said.

Building on this, a joint venture between Thermo Fisher Scientific Inc., the National University Hospital (NUH) Singapore, and MiRXES has been realised to advance detection testing by genomic solutions tailored to the Southeast Asian population. 

“The new, user-friendly testing solutions use NGS for detailed genetic analysis and cancer research to predict cancer progression and suggest personalised treatment plans, ensuring therapies are precisely suited to individual genetic profiles and increasing the likelihood of successful treatment,” GlobalData said.